CANNABIS NEWS

Cannabis News & Research

Policy, science, market & industry — everything moving in the cannabis world.

BREAKING: DEA proposes rescheduling cannabis to Schedule III — biggest federal shift in 50 years MARKET: US legal cannabis market exceeds $33 billion in retail sales in 2024 SCIENCE: FDA approved first plant-derived CBD medication (Epidiolex) for epilepsy POLICY: 24 states + DC now fully legal for adult recreational use RESEARCH: 400,000+ cannabis industry jobs in the US — fastest growing sector BREAKING: DEA proposes rescheduling cannabis to Schedule III — biggest federal shift in 50 years MARKET: US legal cannabis market exceeds $33 billion in retail sales in 2024 SCIENCE: FDA approved first plant-derived CBD medication (Epidiolex) for epilepsy POLICY: 24 states + DC now fully legal for adult recreational use RESEARCH: 400,000+ cannabis industry jobs in the US — fastest growing sector
24Legal States
$33BUS Market 2024
400K+Industry Jobs
Schedule IIIDEA Proposal
38Medical Programs

News by Topic

Click a topic to explore deep-dive guides

Policy
Policy
Legalization & Law
 Research
Science
Research & Medicine
 Industry
Industry
Market & Business
 Strains
Strains
Genetics & Cultivation

Latest Guides & Analysis

In-depth coverage of the most important cannabis topics

DEA Rescheduling Policy
DEA Cannabis Rescheduling: What Schedule III Means
The most significant federal cannabis action since 1970 — how rescheduling affects taxes, banking, and research.
Read Analysis →
Medical Research Research
Cannabis Medical Research: 2024 Evidence Review
FDA-approved CBD for epilepsy, PTSD clinical trials, chronic pain RCTs — the science that now has clinical support.
View Research →
Legal States Legalization
24 Recreational States: 2024 Map & Possession Limits
From Colorado in 2012 to Ohio in 2023 — who's legal, who's next, and what the rules are state by state.
Explore States →
PTSD Research Science
Cannabis & PTSD: What VA Research Now Shows
VA-affiliated researchers publish promising results for nightmare reduction and hyperarousal management.
Read Study →
Cannabis Market Market
$33B US Cannabis Market: Where the Industry Stands
400,000+ jobs, SAFE Banking battles, 280E tax burden — the business of legal cannabis in 2024.
Market Guide →
Terpenes Science
Terpene Science: Beyond THC & CBD
Myrcene, limonene, caryophyllene — how terpenes shape effects and why the entourage effect matters.
Learn More →

Explore All Cannabis Topics

Cannabis Laws Medical Research State Laws Drug Testing Strain Database Growing Guides Cannabis Travel World Map

Key Developments in Cannabis 2024

The DEA’s 2024 proposal to reschedule cannabis from Schedule I to Schedule III is the most significant federal cannabis action in over five decades. Schedule III status would remove the 280E tax burden forcing cannabis businesses to pay 40–70% effective tax rates, allow banking access through FDIC-insured institutions, and dramatically expand legitimate research capacity.

Scientific understanding of cannabinoids, terpenes, and the endocannabinoid system is advancing rapidly. CBD for epilepsy (Epidiolex) is FDA-approved. Clinical evidence for chronic pain, PTSD, and MS spasticity has reached moderate-to-strong status. The US legal market exceeded $33 billion in 2024 with 400,000+ full-time equivalent jobs.

The SAFE Banking Act — protecting banks that serve state-legal cannabis businesses — has passed the House multiple times but awaits Senate action. Its passage remains the industry’s highest near-term federal priority independent of rescheduling.